Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | PLK1 | P53350 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509005 | 0.97 | ATR (0.41) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6517655 | 0.93 | ATR (0.40) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6510521 | 0.93 | ATR (0.40) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6514923 | 0.92 | ATR (0.40) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6513171 | 0.91 | ATR (0.40) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6508960 | 0.91 | ATR (0.41) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6517699 | 0.91 | ATR (0.39) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6510810 | 0.90 | ATR (0.38) | ATRCNR2BRD4DRD2PLK1 | |
| SCHEMBL6511723 | 0.89 | ATR (0.39) | ATRCNR2BRD4DRD2DYRK1A | |
| SCHEMBL6515516 | 0.89 | ATR (0.40) | ATRCNR2BRD4DRD2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ATR 717/4885CNR2 3139/4885BRD4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.